LEADER 03298nam  22005295  450 
001 9910300449703321
005 20200706094130.0
010   $a3-319-95234-X
024 7 $a10.1007/978-3-319-95234-5
035   $a(CKB)4100000006519834
035   $a(MiAaPQ)EBC5511125
035   $a(DE-He213)978-3-319-95234-5
035   $a(PPN)23054214X
035   $a(EXLCZ)994100000006519834
100   $a20180908d2018      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDiffuse Gastric Cancer /$fedited by Tiago Biachi de Castria, Rodrigo Santa Cruz Guindalini
205   $a1st ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018.
215   $a1 online resource (86 pages)
311 08$aPrint version: 3-319-95233-1 
327   $a1. Introduction -- 2. Epidemiology -- 3. The Role of Endoscopy -- 4. Pathology and Molecular Biology -- 5. Genetic Predisposition and Hereditary Syndromes -- 6. The Role of Surgery -- 7. The Role of Radiotherapy -- 8. The Role of Chemotherapy.
330   $aWe live in an era of personalized medicine and the knowledge about pathophysiology of diffuse gastric cancer has had many advances. Thus, the role of this work is to clarify what is new from diagnosis to treatment of this disease in order to treat patients in the most tailored manner as possible. Almost all phase III trials in gastric cancer have been performed without taking in consideration histologic subtypes, i.e. they have disregarded the differences between diffuse gastric cancer and general gastric cancer. However, the clinical practice reveals that diffuse gastric cancer is a completely distinct disease, with an aggressive course and generally worse prognosis. The loss of cohesion between tumor cells due to the loss of E-cadherin synthesis is the critical point on the oncogenesis of diffuse gastric cancer and is at the root of its marked heredity. This book intends to give special attention to Diffuse Gastric Cancer as a particular oncological entity, differentiating it from general gastric cancer, exploring and discussing all its peculiarities, and addressing the basic aspects (pathology and genetics) along with the most recent therapeutic alternatives for this condition.
606   $aOncology
606   $aGastroenterology
606   $aHuman genetics
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aGastroenterology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33061
606   $aHuman Genetics$3https://scigraph.springernature.com/ontologies/product-market-codes/B12008
615  0$aOncology.
615  0$aGastroenterology.
615  0$aHuman genetics.
615 14$aOncology.
615 24$aGastroenterology.
615 24$aHuman Genetics.
676   $a616.99433
702   $ade Castria$b Tiago Biachi$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aGuindalini$b Rodrigo Santa Cruz$4edt$4http://id.loc.gov/vocabulary/relators/edt
712 02$aSpringerLink (Online service)
906   $aBOOK
912   $a9910300449703321
996   $aDiffuse Gastric Cancer$91745048
997   $aUNINA